Donald V. Almeida

Donald V. Almeida recently retired as Vice Chairman of PwC where he led PwC's Global Markets and Industries program, including the Healthcare, Pharmaceutical, Life Sciences and Government practices. Mr. Almeida also served on the US and Global Boards of PwC. He has more than 30 years of experience in PwC's Assurance practice principally with large multinational public companies. He brings to WellDoc extensive experience working with early stage and multinational companies.

He is a member of the American Institute of Certified Public Accountants, the Fordham Business Schools Advisory Board and the Fordham President's Council and will soon be serving on a number of Boards.

Michael I. Greenebaum

Michael I. Greenebaum is president of Greenebaum Enterprises, Inc., a regional real estate development company. Mr. Greenebaum has more than 25 years of experience in all facets of the commercial and residential development industry. He is currently developing Maple Lawn, a 600 acre mixed-use community in Howard County Maryland. Mr. Greenebaum serves on the board of the Greenebaum Family Foundation, which continues the philanthropy of his family by focusing on the improvement of the human condition through education and medicine. He also is a board member for both the University of Maryland Marlene and Stewart Greenebaum Cancer Center and the University of Maryland School of Medicine. He is co-founder of the Maryland Half Marathon and serves on the McDonogh School Board of Trustees, as well as several other civic and community organizations.

David Levy, MD

David Levy has been a champion of patient-centric medicine and the use of technology to disrupt and improve healthcare delivery. As the Global Healthcare Leader, he forged global alliances and developed new business and delivery models for PwC's clients. Under Dr. Levy's leadership, PwC developed a particular focus on mobile health technology and its vast potential in emerging markets.

Dr. Levy began his career as a primary care physician and epidemiologist, successfully founding a large primary care practice in suburban New York City. As a quality consultant for large health insurers, he saw the opportunity to rethink how complex patients were treated in the US healthcare system and created Franklin Health Group, one of the nation's first disease management companies, and led it through a successful acquisition to a global point-of-care diagnostics company.

Terry Lierman

Terry Lierman is a renowned advocate for improving healthcare delivery and supporting medical research. Over the last four decades, his public service has significantly shaped public policy and his entrepreneurial talent has provided for success across the private healthcare and technology sectors.

Mr. Lierman began his career in the public sector at the National Institutes of Health (NIH) and today is frequently noted as one of the most influential persons in healthcare policy. During his years of public service he held U.S. Senate Staff leadership positions including serving as the youngest Staff Director of the Labor Health and Human Services (HHS) Appropriations Committee, leading the Maryland Democratic Party through the successful elections of Governor Martin O'Malley and Senator Ben Cardin, and serving as the Chief of Staff to the House of Representatives Majority Leader and Democratic Whip Congressman Steny H. Hoyer.

In the private sector, Mr. Lierman founded non-profit organizations that advanced healthcare advocacy including the Children's Research Institute at Children's Hospital National Medical Center, National Coalition for Cancer Research, the National Organization on Fetal Alcohol Syndrome (NOFAS), and the Pancreatic Cancer Action Network (PANCAN).

Kevin McRaith

Kevin McRaith, CEO, is guiding the WellDoc team in the successful launch and continued development of the BlueStar Mobile Prescription Therapy. Under his leadership, the WellDoc team has engineered an innovative commercial approach to BlueStar's positioning in the marketplace, and achieved success in the initial targeted launch of BlueStar.

As CEO, Kevin is responsible for the sales, marketing, development and technical teams. His results-driven management team is focused on the successful delivery of technical patient solutions and product training.

Prior to joining WellDoc, Kevin served as Vice President of Sales and Marketing at Human Genome Sciences. In his leadership role with Human Genome Sciences, Kevin hired and led the commercial organization responsible for the successful launch of Benlysta®. During his time in this position, Kevin also chaired the Joint Development Committee, Joint Commercial Committee and the Joint Steering Committee with GlaxoSmithKline.

Kevin also served as Vice President of Sales and Marketing at Hematology Franchise at Genentech where he led the team through the strategic development and sales and marketing execution for Rituxan®. He also managed the pipeline of hematology products.

Prior to his tenure at Genentech, Kevin served in numerous sales and marketing roles of increasing responsibility over 14 years at Abbott Laboratories where he worked on key product launches, including Depakote®, Biaxin®, Kaletra®, Micardis® and Tricor®. His last role at Abbott was General Manager of the Anti-Infective franchise. Prior to Abbott, Kevin started his career at Baxter Healthcare, where he held various roles in sales and marketing.

Dave Stevenson

Dave Stevenson is Managing Director of Merck Global Health Innovation (GHI) Fund. Dave brings over 20 years of healthcare strategy and innovation expertise to the GHI team. In addition, Dave also brings a strong operational focus to accelerating value realization for portfolio companies. Prior to joining the Global Health Innovation Fund, Dave has been a member of Merck's Strategy Office focused on corporate strategy development, including whitespace identification, scenario planning, and transformational business model development. Prior to joining Merck Dave spent a decade in strategy consulting helping small and large health care companies find new growth drivers while freeing up cash flows from operations to fund higher value added activities. Dave started his career with strong cross-functional operating roles with Novartis, including deep experience in Clinical Development and Commercial Operations. Dave holds a BA from Washington University and a MBA from Vanderbilt University.